Braveheart Bio Rings the Opening Bell

About This Event

Braveheart Bio (Nasdaq: BRVE), a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Travis Murdoch, M.D., Chief Executive Officer and President, Braveheart Bio, rings the Opening Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore